Nothing Special   »   [go: up one dir, main page]

WO2011040717A2 - Method for preparing intermediate of sitagliptin using chiral oxirane - Google Patents

Method for preparing intermediate of sitagliptin using chiral oxirane Download PDF

Info

Publication number
WO2011040717A2
WO2011040717A2 PCT/KR2010/006346 KR2010006346W WO2011040717A2 WO 2011040717 A2 WO2011040717 A2 WO 2011040717A2 KR 2010006346 W KR2010006346 W KR 2010006346W WO 2011040717 A2 WO2011040717 A2 WO 2011040717A2
Authority
WO
WIPO (PCT)
Prior art keywords
trifluorophenyl
oxirane
trifluorobenzyl
trifluorobenzene
mixture
Prior art date
Application number
PCT/KR2010/006346
Other languages
French (fr)
Other versions
WO2011040717A3 (en
Inventor
Nam Du Kim
Ji Yeon Chang
Jae Hyuk Jung
Hyun Seung Lee
Dong Jun Kim
Young Kil Chang
Gwan Sun Lee
Original Assignee
Hanmi Holdings Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co., Ltd. filed Critical Hanmi Holdings Co., Ltd.
Publication of WO2011040717A2 publication Critical patent/WO2011040717A2/en
Publication of WO2011040717A3 publication Critical patent/WO2011040717A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/36Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/08Preparation of carboxylic acids or their salts, halides or anhydrides from nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/08Compounds containing oxirane rings with hydrocarbon radicals, substituted by halogen atoms, nitro radicals or nitroso radicals

Definitions

  • the present invention relates to a method for preparing 3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid, particularly (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)- butyric acid, which is a key intermediate in the synthesis of sitagliptin.
  • Sitagliptin phosphate is a selective inhibitor of the second generation dipeptidyl peptidase IV (DPP-4) and used to maintain the systemic concentration of incretin hormone at an optimum level.
  • Sitagliptin phosphate monohydrate was approved by the US Food and Drug Admimstration (FDA) as an adjuvant in dietetics or kinesiatrics for treatment of patients with type-2 diabetes in October 2006 and is marketed in the United States and Korea under the trade name of JANUVIATM (as a single agent) or JANUMETTM (as an oral combination of sitagliptin/Metformin).
  • FDA US Food and Drug Admimstration
  • WO 2004/085661 discloses a method for preparing sitagliptin by reducing an enamine stereoselectively using a platinum-based catalyst, Pt0 2 .
  • WO 2005/097733 discloses a method for preparing sitagliptin by reducing an enamine stereoselectively employing a rhodium-based catalyst, [Rh(cod)Cl] 2 with a chiral diphosphine ligand.
  • WO 2004/087650 discloses a method for preparing sitagliptin phosphate from (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid through the five- step processes shown in Reaction Scheme 1 :
  • Bn is benzyl
  • WO 2004/087650 also discloses a method for preparing (3S)-3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid, a key sitagliptin intermediate, comprising the steps of: conducting a stereoselective reduction of methyl 4-(2,4,5-trifluorophenyl)-3-oxobutyrate in the presence of (S)-BINAP-RuCl 2 -Et 3 N under a high hydrogen pressure, and hydrolyzing the resulting compound, as shown in Reaction Scheme 2:
  • KRED-NADH- 110TM is a trade name of the ketoreductase enzyme (Codexis, Redwood City, CA) and A-KRED-NADH is a recycle mixture containing KRED-NADH.
  • the 2-(2,4,5-trifluorobenzyl)-oxirane is (2S)-2-(2,4,5-trifluorobenzyl)- oxirane of formula (lib):
  • the present invention is characterized in that 3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid, particularly (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)- butyric acid, which is a key intermediate in the synthesis of sitagliptin, is prepared by using a chiral oxirane with a high yield and at a low cost.
  • the inventive method comprises the steps of: subjecting 2-(2,4,5- trifluorobenzyl)-oxirane of formula (11a) to ⁇ -hydrocyanation in the presence of a catalyst to obtain 4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile of formula (Ilia); and hydrolyzing the 4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile in the presence of a strong base to obtain 3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid of formula (la).
  • the inventive method comprises the steps of: subjecting (2S)-2-(2,4,5- trifluorobenzyl)-oxirane of formula (lib) to ⁇ -hydrocyanation in the presence of a catalyst to obtain (3S)-4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile of formula
  • step 2 hydrolyzing the (3S)-4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile in the presence of a strong base to obtain (3S)-3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid of formula (lb) (step 2):
  • the (3S)-4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile of formula (Illb) is prepared by subjecting (2S)-2-(2,4,5-trifluorobenzyl)-oxirane of formula (lib) to ⁇ - hydrocyanation in the presence of a catalyst.
  • (2S)-2-(2,4,5-trifluorobenzyl)-oxirane of formula (lib) is dissolved in a solvent and conducted a ⁇ -hydrocyanation by adding sodium cyanide in the presence of a catalyst to obtain (3S)-4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile of formula (Illb).
  • the (2S)-2-(2,4,5-trifluorobenzyl)-oxirane is a novel compound and may be prepared by treating a 2,4,5-trifluorobenzene halide as a starting material with a (S)- epihalohydrin (Route 1); or by treating the 2,4,5-trifluorobenzene halide with a allyl halide (Route 2) as shown in Reaction Scheme 6: Reaction Scheme 6
  • m-CPBA is m-chloroperoxybenzoic acid.
  • the method for preparing (2S)-2-(2,4,5-trifluorobenzyl)-oxirane according to Route 1 comprises the steps of: preparing a Grignard reagent using a 2,4,5- trifluorobenzene halide; arylating a (S)-epihalohydrin using the Grignard reagent in the presence of a copper halide to obtain (2S)-3-(2,4,5-trifluorophenyl)-l-halo-2-propanol; and conducting an epoxidation reaction of the (2S)-3-(2,4,5-trifluorophenyl)-l-halo-2- propanol in the presence of a strong base.
  • the 2,4,5 -trifluorobenzene halide is treated with magnesium (Mg) and organic alkyl halide (e.g., 1,2-dibromoethane); Mg and I 2 ; or isopropyl magnesium chloride (z ' -PrMgCl) to obtain a Grignard reagent.
  • Mg magnesium
  • organic alkyl halide e.g., 1,2-dibromoethane
  • I 2 e.g., 1,2-dibromoethane
  • z -PrMgCl isopropyl magnesium chloride
  • 2,4,5-trifluorobenzene halide examples include 2,4,5-trifluorobenzene bromide, 2,4,5-trifluorobenzene chloride, and a mixture thereof.
  • (2S)-3-(2,4,5-trifluorophenyl)-l-halo-2-propanol is prepared by arylating the (S)-epihalohydrin using the Grignard reagent.
  • the Grignard reagent is mixed with a catalytic amount of the copper halide, and then the (S)-epihalohydrin is added thereto slowly at a low temperature to obtain (2S)-3-(2,4,5-trifluorophenyl)-l- halo-2-propanol.
  • Examples of the copper halide include CuBr, Cul, and a mixture thereof, preferably Cul.
  • the oxirane such as (S)-epihalohydrin comprises (S) and (R) isomer which are commercially available.
  • Examples for the (S)-epihalohydrin include (S)- epichlorohydrin.
  • (2S)-2-(2,4,5-trifluorobenzyl)-oxirane is prepared by dissolving (2S)-3- (2,4,5-trifluorophenyl)-l-halo-2-propanol into a solvent and conducting an epoxidation reaction of a strong base.
  • solvent examples include tetrahydrofuran, diethylether, and the like.
  • the strong base examples include a alkali metal hydroxide such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and a mixture thereof, preferably sodium hydroxide.
  • the method for preparing (2S)-2-(2,4,5-trifluorobenzyl)-oxirane according to Route 2 comprises the steps of: preparing a Grignard reagent using a 2,4,5- trifluorobenzene halide; arylating an allyl halide with the Grignard reagent to obtain 3- (2,4,5-trifluorophenyl)-l-propene; conducting an epoxidation reaction of 3-(2,4,5- trifluorophenyl)-l-propene using an oxidant to obtain a racemic 2-(2,4,5- trifluorobenzyl)-oxirane; and carrying out selective hydrolytic kinetic resolution (HKR) of the racemic 2-(2,4,5,-tifluorobenzyl)-oxirane using (S,S)-Co-salen.
  • HLR hydrolytic kinetic resolution
  • a Grignard reagent is prepared using a 2,4,5-trifluorobenzene halide.
  • the methods for preparing the 2,4,5-trifluorobenzene halide and the Grignard reagent using the same are the same as described above.
  • an allyl halide is arylated using the Grignard reagent at a low temperature to obtain 3-(2,4,5-trifluorophenyl)-l-propene.
  • allyl halide examples include allyl bromide and the like.
  • solvent examples include tetrahydrofuran, diethylether, and the like.
  • oxidant examples include m-ClC ⁇ CCbH, CH 3 C0 3 H, CF 3 C0 3 H, H 2 0 2 , and a mixture thereof, preferably m-ClC 6 H 4 C0 3 H.
  • (2S)-2-(2,4,5-trifluorobenzyl)-oxirane is prepared by conducting a selective HKR of the racemic 2-(2,4,5,-tifluorobenzyl)-oxirane using (S,S)-Co-salen of formula (IV):
  • the ⁇ -hydrocyanation of the (2S)-2-(2,4,5-trifluorobenzyl)-oxirane is conducted in a solvent such as dimethylformamide (DMF), dimethylsulfoxide (DMSO), or d to C 6 alcohol ⁇ e.g., methanol, ethanol, and isopropanol), preferably DMF.
  • a solvent such as dimethylformamide (DMF), dimethylsulfoxide (DMSO), or d to C 6 alcohol ⁇ e.g., methanol, ethanol, and isopropanol, preferably DMF.
  • the ⁇ -hydrocyanation is conducted in the presence of a catalyst such as H4CI, citric acid, acetic acid, formic acid, maleic acid, or a mixture thereof, preferably NH 4 CI.
  • a catalyst such as H4CI, citric acid, acetic acid, formic acid, maleic acid, or a mixture thereof, preferably NH 4 CI.
  • the 3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid preferably (3S)-3-hydroxy- 4-(2,4,5-trifluorophenyl)-butyric acid is prepared by hydrolyzing (3S)-4-(2,4,5- trifluorophenyl)-3-hydroxybutane nitrile obtained in Step 1 in the presence of a strong base and H 2 0 2 .
  • the strong base examples include an alkali metal hydroxide such as sodium hydroxide (NaOH), potassium hydroxide (KOH), lithium hydroxide (LiOH) or a mixture thereof, preferably sodium hydroxide.
  • the strong base is used in a form of aqueous solution.
  • the method according to the present invention makes it possible to easily prepare 3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid, particularly (3S)-3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid, a key intermediate in the synthesis of sitagliptin, with a high yield and a low cost, which is suitable for mass production of sitagliptin.
  • Step 1 preparation of (2S)-3-(2A5-trifluorophenyl -chloro-2-prepanol
  • Magnesium (Mg) (1.26 g) was added to tetrahydrofuran (THF) (10 ml) and a drop of 1 ,2-dibromomethane was added thereto.
  • THF tetrahydrofuran
  • 2,4,5- trifluorobenzene bromide (0.55 g) was added slowly, and then stirred for 30 min.
  • 2,4,5-trifluorobenzene bromide (9.0 g) in THF (50 ml) was added dropwise over 30 min and then stirred at room temperature for 1 hr.
  • Step 2 Preparation of (2S)-2-(2,4,5-trifluorobenzyl -oxirane (2S)-3-(2,4,5-Trifluorophenyl)-l-chloro-2-propanol obtained in step 1 was dissolved in methanol (50 ml) and an aqueous solution of NaOH (2.3 g) was added thereto dropwise. The resulting mixture was stirred for 1 hr and condensed under a reduced pressure to remove methanol. The residue was mixed with water (50 ml) and ethyl acetate (50 ml) to induce phase separation. The organic layer was isolated, washed with aq. saturated sodium chloride solution (50 ml), dried over MgS0 4 , and filtered off MgSO 4 . The residue was condensed under a reduced pressure to remove the organic solvent to obtain the title compound (6.8 g, yield: 80 %).
  • (2S)-3-(2,4,5-trifluorophenyl)-l-chloro-2-propanol obtained in step 1 was dissolved in methanol (50 ml) and NaOH (2.3 g) was added thereto dropwise. The resulting mixture was stirred for 1 hr and condensed under a reduced pressure to remove methanol. The residue was mixed with water (50 ml) and ethyl acetate (50 ml) to induce phase separation. The organic layer was isolated, washed with aq. saturated sodium chloride solution (50 ml), dried over MgS0 4 , and filtered off MgS0 4 . The residue was condensed under a reduced pressure to remove the organic solvent to obtain the title compound (7.6 g, yield: 85 %).
  • allyl bromide (18.0 g) in THF (60 ml) was added dropwise over 20 min and then stirred for 1 hrs. The temperature of the resulting mixture was increased to room temperature and then stirred for 1 hr.
  • Dichloromethane (MC) 300 ml was added to the resulting mixture to induce phase separation. The organic layer was isolated, washed with 2 M NH 4 CI (150 ml) and water (150 ml) successively, dried over MgS0 4 , and filtered off MgS0 4 . The residue was condensed under a reduced pressure to remove the organic solvent to obtain the title compound.
  • 3-(2,4,5-Trifiuorophenyl)-l-propene obtained in step 1 was dissolved in dichloromethane (300 ml) and m-chloroperoxybenzoic acid (m-CPBA) (35 g) was added thereto dropwise. The resulting mixture was stirred for 17 hr and then saturated NaHC0 3 (300 ml) was added thereto to induce phase separation. The organic layer was isolated, washed with 1 N NaOH (300 ml) and brine (100 ml) successively, dried over MgS0 4 , and filtered off MgS0 4 . The residue was condensed under a reduced pressure to remove the organic solvent to obtain the title compound (19.1 g, yield: 75 %).
  • m-CPBA m-chloroperoxybenzoic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Disclosed is: a novel, simple and low-cost method for preparing 3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid, particularly (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid, which is used as a key intermediate in the preparation of sitagliptin.

Description

METHOD FOR PREPARING INTERMEDIATE OF SITAGLIPTIN
USING CHIRAL OXIRANE
FIELD OF THE INVENTION
The present invention relates to a method for preparing 3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid, particularly (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)- butyric acid, which is a key intermediate in the synthesis of sitagliptin. BACKGROUND OF THE INVENTION
Sitagliptin phosphate is a selective inhibitor of the second generation dipeptidyl peptidase IV (DPP-4) and used to maintain the systemic concentration of incretin hormone at an optimum level. Sitagliptin phosphate monohydrate was approved by the US Food and Drug Admimstration (FDA) as an adjuvant in dietetics or kinesiatrics for treatment of patients with type-2 diabetes in October 2006 and is marketed in the United States and Korea under the trade name of JANUVIA™ (as a single agent) or JANUMET™ (as an oral combination of sitagliptin/Metformin).
Various methods for preparing sitagliptin phosphate have been developed. For example, WO 2004/085661 discloses a method for preparing sitagliptin by reducing an enamine stereoselectively using a platinum-based catalyst, Pt02. WO 2005/097733 discloses a method for preparing sitagliptin by reducing an enamine stereoselectively employing a rhodium-based catalyst, [Rh(cod)Cl]2 with a chiral diphosphine ligand.
The document [J. Am. Chem. Soc, 2009, 131, p.l 1316-11317] discloses a method for preparing sitagliptin by reducing an enamine stereoselectively using a ruthenium-based catalyst, Ru(OAc)2 with a chiral diphosphine ligand, and WO 2009/064476 discloses a method for preparing sitagliptin by reducing an enamine stereoselectively using Ru(OAc)2 and a chiral diphosphine ligand, or using a chiral acid together with a borohydride reducing agent such as NaBH4.
On the other hand, there has been developed a method for preparing sitagliptin phosphate by using 3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid, (3S)-3-hydroxy-4- (2,4,5-trifluorophenyl)-butyric acid in particular, as a key intermediate. For example, WO 2004/087650 discloses a method for preparing sitagliptin phosphate from (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid through the five- step processes shown in Reaction Scheme 1 :
Reaction Scheme 1
Figure imgf000003_0001
Figure imgf000003_0002
wherein, Bn is benzyl.
WO 2004/087650 also discloses a method for preparing (3S)-3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid, a key sitagliptin intermediate, comprising the steps of: conducting a stereoselective reduction of methyl 4-(2,4,5-trifluorophenyl)-3-oxobutyrate in the presence of (S)-BINAP-RuCl2-Et3N under a high hydrogen pressure, and hydrolyzing the resulting compound, as shown in Reaction Scheme 2:
Reaction Scheme 2
Figure imgf000003_0003
Yield : 83% Ee : 94%ee wherein, Me is methyl and BINAP is 2,2'-bis(diphenylphosphino)-l,l'- binaphthyl. Further, WO 2009/045507 discloses methods for preparing methyl (S)- and (R)- enantiomers of 3-hydroxy-4-(2,4,5-trifluorophenyl)-butyrate, a key sitagliptin intermediate, via the stereoselective enzymatic reduction of methyl 4-(2,4,5- trifluorophenyl)-3-oxobutyrate using an enzyme, as shown in Reaction Schemes 3 and 4:
Reaction Scheme 3
Figure imgf000004_0001
Yield : 86%<
Ee : 96.6%ee
wherein, KRED-NADH- 110™ is a trade name of the ketoreductase enzyme (Codexis, Redwood City, CA) and A-KRED-NADH is a recycle mixture containing KRED-NADH.
However, the above methods must be carried out under a high hydrogen pressure in the presence of a ruthenium catalyst, or using a ketone reducing enzyme to obtain (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid having a chiral center at the 3- position.
The present inventors have therefore endeavored to develop a novel method for preparing sitagliptin which is free from the above-mentioned problems associated with the conventional methods and unexpectedly found that (3S)-3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid can be prepared by a simple and low-cost method using (2S)-2-(2,4,5-trifluorobenzyl)-oxirane prepared from the commercially available (S)- epichlorohydrin.
SUMMARY OF THE INVENTION Accordingly, it is an object of the present invention to provide a novel method for preparing 3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid, particularly (3S)-3-hydroxy- 4-(2,4,5-trifluorophenyl)-butyric acid, which is a key intermediate in the synthesis of sitagliptin.
It is another object of the present invention to provide (2S)-2-(2,4,5- trifluorobenzyl)-oxirane and 4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile which are used in the preparation of 3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid.
In accordance with an aspect of the present invention, there is provided a method for preparing 3-hydroxy-4-(2,4,5-trifluorophenyl)butyric acid of formula (la), comprising the steps of:
subjecting 2-(2,4,5-trifluorobenzyl)-oxirane of formula (Ila) to β-hydrocyanation in the presence of a catalyst to obtain 4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile of formula (Ilia); and
hydrolyzing the 4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile in the presence of a strong base:
Figure imgf000005_0001
Preferably, the 2-(2,4,5-trifluorobenzyl)-oxirane is (2S)-2-(2,4,5-trifluorobenzyl)- oxirane of formula (lib):
Figure imgf000006_0001
In accordance with an aspect of the present invention, there is provided (2S)-2- (2,4,5-trifluorobenzyl)-oxirane of formula (lib) and 4-(2,4,5-trifluorophenyl)-3- hydroxybutane nitrile of formula (Ilia), which are used in the preparation of 3-hydroxy- 4-(2,4,5-trifluorophenyl)-butyric acid.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is characterized in that 3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid, particularly (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)- butyric acid, which is a key intermediate in the synthesis of sitagliptin, is prepared by using a chiral oxirane with a high yield and at a low cost.
The inventive method comprises the steps of: subjecting 2-(2,4,5- trifluorobenzyl)-oxirane of formula (11a) to β-hydrocyanation in the presence of a catalyst to obtain 4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile of formula (Ilia); and hydrolyzing the 4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile in the presence of a strong base to obtain 3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid of formula (la).
Preferably, the inventive method comprises the steps of: subjecting (2S)-2-(2,4,5- trifluorobenzyl)-oxirane of formula (lib) to β-hydrocyanation in the presence of a catalyst to obtain (3S)-4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile of formula
(Illb) (step 1); and hydrolyzing the (3S)-4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile in the presence of a strong base to obtain (3S)-3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid of formula (lb) (step 2):
Figure imgf000006_0002
Figure imgf000007_0001
The method for preparing (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid using (2S)-2-(2,4,5-trifluorobenzyl)-oxirane as a starting material according to the present invention is shown in Reaction Scheme 5, but not limited thereto.
Reaction Scheme 5
Figure imgf000007_0002
(Illb) (lb)
Hereinafter, description of the preparation method illustrated in Reaction Scheme 5 by each step will be given in detail.
<Step 1>
The (3S)-4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile of formula (Illb) is prepared by subjecting (2S)-2-(2,4,5-trifluorobenzyl)-oxirane of formula (lib) to β- hydrocyanation in the presence of a catalyst.
Particularly, (2S)-2-(2,4,5-trifluorobenzyl)-oxirane of formula (lib) is dissolved in a solvent and conducted a β-hydrocyanation by adding sodium cyanide in the presence of a catalyst to obtain (3S)-4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile of formula (Illb).
The (2S)-2-(2,4,5-trifluorobenzyl)-oxirane is a novel compound and may be prepared by treating a 2,4,5-trifluorobenzene halide as a starting material with a (S)- epihalohydrin (Route 1); or by treating the 2,4,5-trifluorobenzene halide with a allyl halide (Route 2) as shown in Reaction Scheme 6: Reaction Scheme 6
Figure imgf000008_0001
wherein, m-CPBA is m-chloroperoxybenzoic acid.
Route 1
The method for preparing (2S)-2-(2,4,5-trifluorobenzyl)-oxirane according to Route 1 comprises the steps of: preparing a Grignard reagent using a 2,4,5- trifluorobenzene halide; arylating a (S)-epihalohydrin using the Grignard reagent in the presence of a copper halide to obtain (2S)-3-(2,4,5-trifluorophenyl)-l-halo-2-propanol; and conducting an epoxidation reaction of the (2S)-3-(2,4,5-trifluorophenyl)-l-halo-2- propanol in the presence of a strong base.
Particularly, the 2,4,5 -trifluorobenzene halide is treated with magnesium (Mg) and organic alkyl halide (e.g., 1,2-dibromoethane); Mg and I2; or isopropyl magnesium chloride (z'-PrMgCl) to obtain a Grignard reagent.
Examples of the 2,4,5-trifluorobenzene halide include 2,4,5-trifluorobenzene bromide, 2,4,5-trifluorobenzene chloride, and a mixture thereof.
Next, (2S)-3-(2,4,5-trifluorophenyl)-l-halo-2-propanol is prepared by arylating the (S)-epihalohydrin using the Grignard reagent. Preferably, the Grignard reagent is mixed with a catalytic amount of the copper halide, and then the (S)-epihalohydrin is added thereto slowly at a low temperature to obtain (2S)-3-(2,4,5-trifluorophenyl)-l- halo-2-propanol.
Examples of the copper halide include CuBr, Cul, and a mixture thereof, preferably Cul.
The oxirane such as (S)-epihalohydrin comprises (S) and (R) isomer which are commercially available. Examples for the (S)-epihalohydrin include (S)- epichlorohydrin.
Then, (2S)-2-(2,4,5-trifluorobenzyl)-oxirane is prepared by dissolving (2S)-3- (2,4,5-trifluorophenyl)-l-halo-2-propanol into a solvent and conducting an epoxidation reaction of a strong base.
Examples of the solvent include tetrahydrofuran, diethylether, and the like.
Examples of the strong base include a alkali metal hydroxide such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and a mixture thereof, preferably sodium hydroxide.
Route 2
The method for preparing (2S)-2-(2,4,5-trifluorobenzyl)-oxirane according to Route 2 comprises the steps of: preparing a Grignard reagent using a 2,4,5- trifluorobenzene halide; arylating an allyl halide with the Grignard reagent to obtain 3- (2,4,5-trifluorophenyl)-l-propene; conducting an epoxidation reaction of 3-(2,4,5- trifluorophenyl)-l-propene using an oxidant to obtain a racemic 2-(2,4,5- trifluorobenzyl)-oxirane; and carrying out selective hydrolytic kinetic resolution (HKR) of the racemic 2-(2,4,5,-tifluorobenzyl)-oxirane using (S,S)-Co-salen.
Particularly, a Grignard reagent is prepared using a 2,4,5-trifluorobenzene halide. The methods for preparing the 2,4,5-trifluorobenzene halide and the Grignard reagent using the same are the same as described above.
Then, an allyl halide is arylated using the Grignard reagent at a low temperature to obtain 3-(2,4,5-trifluorophenyl)-l-propene.
Examples for the allyl halide include allyl bromide and the like.
Next, a reacemic 2-(2,4,5-trifluorobenzxyl)-oxirane is prepared by dissolving 3-
(2,4,5-trifluorophenyl)-l-propene in a solvent and adding an oxidant thereto to induce an epoxidation.
Examples of the solvent include tetrahydrofuran, diethylether, and the like.
Examples of the oxidant include m-ClC^CCbH, CH3C03H, CF3C03H, H202, and a mixture thereof, preferably m-ClC6H4C03H.
Then, optionally (2S)-2-(2,4,5-trifluorobenzyl)-oxirane is prepared by conducting a selective HKR of the racemic 2-(2,4,5,-tifluorobenzyl)-oxirane using (S,S)-Co-salen of formula (IV):
Figure imgf000010_0001
The method for preparing the desired chiral oxirane via selective HKR of the terminal oxirane has been disclosed in the documents [see Tetrahedron Asymmetry, 2003, 14, 1407-1446, and J Am. Chem. Soc, 2002, 124, 1307-1315].
The β-hydrocyanation of the (2S)-2-(2,4,5-trifluorobenzyl)-oxirane is conducted in a solvent such as dimethylformamide (DMF), dimethylsulfoxide (DMSO), or d to C6 alcohol {e.g., methanol, ethanol, and isopropanol), preferably DMF.
The β-hydrocyanation is conducted in the presence of a catalyst such as H4CI, citric acid, acetic acid, formic acid, maleic acid, or a mixture thereof, preferably NH4CI.
<Step 2>
The 3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid, preferably (3S)-3-hydroxy- 4-(2,4,5-trifluorophenyl)-butyric acid is prepared by hydrolyzing (3S)-4-(2,4,5- trifluorophenyl)-3-hydroxybutane nitrile obtained in Step 1 in the presence of a strong base and H202.
Examples of the strong base include an alkali metal hydroxide such as sodium hydroxide (NaOH), potassium hydroxide (KOH), lithium hydroxide (LiOH) or a mixture thereof, preferably sodium hydroxide. Preferably, the strong base is used in a form of aqueous solution.
The method according to the present invention makes it possible to easily prepare 3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid, particularly (3S)-3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid, a key intermediate in the synthesis of sitagliptin, with a high yield and a low cost, which is suitable for mass production of sitagliptin.
Further, the (2S)-2-(2,4,5-trifluorobenzyl)-oxirane and 4-(2,4,5-trifluorophenyl)- 3 -hydroxy butane nitrile which are used in preparing (3S)-3-hydroxy-4-(2,4,5- trifluorophenyl)-butyric acid as a intermediate, are novel compound. Accordingly, the present invention provides the (2S)-2-(2,4,5-trifluorobenzyl)-oxirane and 4-(2,4,5- trifluorophenyl)-3-hydroxybutane nitrile. The following preparative examples and examples illustrate the embodiments of the present invention in more detail. However, the following preparative examples and examples of the present invention are merely examples, and the present invention is not limited thereto. Preparation Example 1: Preparation of (2S)-2-(2,4,5-trifluorobenzyI)-oxirane
Figure imgf000011_0001
Step 1: preparation of (2S)-3-(2A5-trifluorophenyl -chloro-2-prepanol Magnesium (Mg) (1.26 g) was added to tetrahydrofuran (THF) (10 ml) and a drop of 1 ,2-dibromomethane was added thereto. To the resulting mixture, 2,4,5- trifluorobenzene bromide (0.55 g) was added slowly, and then stirred for 30 min. To the reaction mixture thus obtained, 2,4,5-trifluorobenzene bromide (9.0 g) in THF (50 ml) was added dropwise over 30 min and then stirred at room temperature for 1 hr. Cul (0.72 g) was added thereto and the temperature of the resulting reaction mixture was lowered to 0 °C. To the cooled reaction mixture, (S)-epichlorohydrin (4.1 ml) in THF (40 ml) was added dropwise over 30 min, and then stirred for 2 hrs at room temperature. Saturated NH4CI (50 ml) and ethyl acetate (50 ml) were added to the resulting mixture to induce phase separation. The organic layer was isolated, washed with aq. saturated sodium chloride solution (50 ml), dried over MgS04, and filtered off MgS04. The residue was condensed under a reduced pressure to remove the organic solvent to obtain the title compound.
Step 2: Preparation of (2S)-2-(2,4,5-trifluorobenzyl -oxirane (2S)-3-(2,4,5-Trifluorophenyl)-l-chloro-2-propanol obtained in step 1 was dissolved in methanol (50 ml) and an aqueous solution of NaOH (2.3 g) was added thereto dropwise. The resulting mixture was stirred for 1 hr and condensed under a reduced pressure to remove methanol. The residue was mixed with water (50 ml) and ethyl acetate (50 ml) to induce phase separation. The organic layer was isolated, washed with aq. saturated sodium chloride solution (50 ml), dried over MgS04, and filtered off MgSO4. The residue was condensed under a reduced pressure to remove the organic solvent to obtain the title compound (6.8 g, yield: 80 %).
'H-NMR(300MHz, CDC13) : δ 7.17-7.05 (2H, m), 6.96-6.88 (2H, m), 3.16-3.13 (1H, m) 3.14 (1H, dd, J=4.68, 14.7), 2.82-2.77 (2H, m), 2.54-2.47 (1H, m).
Preparation Example 2: Preparation of (2S)-2-(2,4,5-trifluorobenzyl)-oxirane
Figure imgf000012_0001
Step 1 : Preparation of (2SV3-(2.4,5-trifluorophenvn-l-chloro-2-propanol
2N -PrMgCl in THF (26 ml) was added to 2,4,5-trifluorobenzene bromide (9.55 g) in THF (30 ml) dropwise at -15 °C for lhr. Cul (0.72 g) was added thereto at -15 °C and raised the temperature of the resulting mixture to -10 °C. To the resulting mixture, (S)-epichlorohydrin (4.1 ml) in THF (40 ml) was added dropwise over 30 min and then stirred at 0 °C for 1 hr. Saturated N¾C1 (50 ml) and ethyl acetate (50 ml) were added to the resulting reaction mixture to induce phase separation. The organic layer was isolated, washed with aq. saturated sodium chloride solution (50 ml), dried over MgS04, and filtered off MgS04. The residue was condensed under a reduced pressure to remove the organic solvent to obtain the title compound.
Step 2: preparation of (2S -2-(2,4,5-trifluorobenzylVoxirane
(2S)-3-(2,4,5-trifluorophenyl)-l-chloro-2-propanol obtained in step 1 was dissolved in methanol (50 ml) and NaOH (2.3 g) was added thereto dropwise. The resulting mixture was stirred for 1 hr and condensed under a reduced pressure to remove methanol. The residue was mixed with water (50 ml) and ethyl acetate (50 ml) to induce phase separation. The organic layer was isolated, washed with aq. saturated sodium chloride solution (50 ml), dried over MgS04, and filtered off MgS04. The residue was condensed under a reduced pressure to remove the organic solvent to obtain the title compound (7.6 g, yield: 85 %).
Preparation Example 3: Preparation of 2-(2,4,5-trifluorobenzyl)-oxirane
Figure imgf000013_0001
Step 1: Preparation 3-(2A5-trifluorophenyl -l-propene
Mg (1.26 g) was added to THF (30 ml) and a drop of 1 ,2-dibromomethane (0.2 g) was added thereto. To the resulting mixture, 2,4,5-trifluorobenzene bromide (3.6 g) was added slowly and then stirred for 30 min. To the reaction mixture thus obtained, 2,4,5-trifluorobenzene bromide (25 g) in THF (60 ml) was added dropwise over 60 min and then stirred at room temperature for 1 hr. The temperature of the resulting mixture was lowered to -10 °C . To the cooled mixture, allyl bromide (18.0 g) in THF (60 ml) was added dropwise over 20 min and then stirred for 1 hrs. The temperature of the resulting mixture was increased to room temperature and then stirred for 1 hr. Dichloromethane (MC) (300 ml) was added to the resulting mixture to induce phase separation. The organic layer was isolated, washed with 2 M NH4CI (150 ml) and water (150 ml) successively, dried over MgS04, and filtered off MgS04. The residue was condensed under a reduced pressure to remove the organic solvent to obtain the title compound.
Step 2: Preparation of 2-(2,4,5-trifluorobenzyl')-oxirane
3-(2,4,5-Trifiuorophenyl)-l-propene obtained in step 1 was dissolved in dichloromethane (300 ml) and m-chloroperoxybenzoic acid (m-CPBA) (35 g) was added thereto dropwise. The resulting mixture was stirred for 17 hr and then saturated NaHC03 (300 ml) was added thereto to induce phase separation. The organic layer was isolated, washed with 1 N NaOH (300 ml) and brine (100 ml) successively, dried over MgS04, and filtered off MgS04. The residue was condensed under a reduced pressure to remove the organic solvent to obtain the title compound (19.1 g, yield: 75 %).
Preparation Example 4: Preparation of (2S)-2-(2,4,5-trifluorobenzyl)-oxirane
Figure imgf000014_0001
(S,S)-Co-salen (302 mg), 2-(2,4,5-trifluorobenzyl)-oxirane (18.8 g), acetic acid
(AcOH) (120 uL) and THF(1 mL) were mixed in a reactor at room temperature. The temperatue of the resulting mixture was lowered to 0 °C and H20 (1.0 ml) was added thereto. The mixture thus obtained was stirred at room temperature for 24 hrs and condensed under a reduced pressure to remove THF. The residue was subjected to column chromatography to obtain the title compound (7.71 g, yield: 41 %).
Preparation Example 5: Preparation of (3S)-4-(2,4,5-trifluorophenyl)-3- hydroxybutane nitrile
Figure imgf000014_0002
To a solution of (2S)-2-(2,4,5-trifluorobenzyl)-oxirane (5.30 g) in MeOH (25 ml), NaCN (2.07 g) in water (10 ml) and NH4C1 (1.96 g) were added successively and warmed up to 50 °C . The resulting mixture was stirred for 3 hrs and condensed under a reduced pressure to remove the solvent. The residue was mixed with water (25 ml) and ethyl acetate (25 ml) to induce phase separation. The organic layer was isolated, washed with aq. saturated sodium chloride solution (25 ml) twice, dried over MgS04, filtered off MgS04, and condensed under a reduced pressure to remove the organic solvent. The residue was subjected to column chromatography to obtain the title compound (5.59 g, yield: 92 %).
'H-NMR(300MHz, CDC13) : δ 7.19-7.08 (2H, m), 6.99-6.90 (2H, m), 4.24-4.15 (1H, m), 2.96-2.83 (2H, m), 2.65-2.48 (2H, m)
Example 1: Preparation of (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid
Figure imgf000015_0001
(3S)-4-(2,4,5-Trifluorophenyl)-3-hydroxybutane nitrile (5.59 g) obtained in Preparation Example 5 was dissolved in MeOH (20 ml) in a reactor at room temperature and 30 % H202 (5.31 mL) and NaOH (2.60 g) were added thereto successively. The resulting mixture was warmed up 70 °C and refluxed for 6 hrs with stirring. The temperature of the resulting mixture was lowered to 0 °C and 2N HCl (aq) (28.0 mL) was added slowly thereto. The mixture thus obtained was extracted with ethyl acetate (30 ml) to induce phase separation. The organic layer was isolated, washed with aq. saturated sodium chloride solution (30 ml) twice, dried over MgS04, filtered off MgS04, and condensed under a reduced pressure to remove the organic solvent. The residue was subjected to column chromatography to obtain the title compound (5.48 g, yield: 90 %).
'H-NMR(300MHz, CDC13) : δ 7.27-7.07 (2H, m), 6.96-6.86 (2H, m), 6.0 (1H, br), 4.30-4.22 (m, 1H), 2.79 (2H, d, J=6.3), 2.61-2.44 (m, 2H)
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A method for preparing 3-hydroxy-4-(2,4,5-trifluorophenyl)butyric acid of formula (la), comprising the steps of:
subjecting 2-(2,4,5-trifluorobenzyl)-oxirane of formula (Ila) to β- hydrocyanation in the presence of a catalyst to obtain 4-(2,4,5-trifluorophenyl)-3- hydroxybutane nitrile of formula (Ilia); and
hydrolyzing the 4-(2,4,5-trifluorophenyl)-3-hydroxybutane nitrile in the presence of a strong base:
Figure imgf000016_0001
F (Ilia).
2. The method of claim 1, wherein the 2-(2,4,5-trifluorobenzyl)-oxirane is (2S)-2- (2,4,5-trifluorobenzyl)-oxirane of formula (lib):
Figure imgf000016_0002
3. The method of claim 1, wherein the catalyst is selected from the group consisting of NH4CI, citric acid, acetic acid, formic acid, maleic acid, and a mixture thereof.
4. The method of claim 1, wherein the β-hydrocyanation is conducted by using sodium cyanide.
5. The method of claim 1, wherein the strong base is selected from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, and a mixture thereof.
6. The method of claim 1, wherein the 2-(2,4,5-trifluorobenzyl)-oxirane is prepared by a method comprising the steps of:
preparing a Grignard reagent using a 2,4,5-trifluorobenzene halide;
arylating a (S)-epihalohydrin in the presence of a copper halide to obtain (2S)-3- (2,4,5-trifluorophenyl)-l-halo-2-propanol using the Grignard reagent; and
conducting an epoxidation reaction of the (2S)-3-(2,4,5-trifluorophenyl)-l-halo- 2-propanol in the presence of a strong base.
7. The method of claim 6, wherein the 2,4,5-trifluorobenzene halide is selected from the group consisting of 2,4,5-trifluorobenzene bromide, 2,4,5-trifluorobenzene chloride, and a mixture thereof.
8. The method of claim 6, wherein the copper halide is selected from the group consisting of CuBr, Cul, and a mixture thereof.
9. The method of claim 6, wherein the strong base is selected from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, and a mixture thereof.
10. The method of claim 1, wherein 2-(2,4,5-trifluorobenzyl)-oxirane is prepared by a method comprising the steps of:
preparing a Grignard reagent using a 2,4,5-trifluorobenzene halide;
arylating an allyl halide with the Grignard reagent to obtain 3-(2,4,5- trifluorophenyl)- 1 -propene; conducting an epoxidation reaction of the 3-(2,4,5-trifluorophenyl)-l-propene using an oxidant to obtain a racemic 2-(2,4,5,-tifluorobenzyl)-oxirane; and
carrying out selective hydrolytic kinetic resolution of the racemic 2-(2,4,5,- tifluorobenzyl)-oxirane.
11. The method of claim 10, wherein the 2,4,5-trifluorobenzene halide is selected from the group consisting of 2,4,5-trifluorobenzene bromide, 2,4,5-trifluorobenzene chloride, and a mixture thereof.
12. The method of claim 10, wherein the oxidant is selected from the group consisting of m-ClCetLtCOsH, CH3CO3H, CF3CO3H, H202, and a mixture thereof.
13. The method of claim 10, wherein the selective hydrolytic kinetic resolution is conducted using (S,S)-Co-salen of formula (IV):
Figure imgf000018_0001
(IV).
14. (2S)-2-(2,4,5-trifluorobenzyl)-oxirane of formula (lib):
Figure imgf000018_0002
F (lib).
15. 4-(2,4,5-Trifluorophenyl)-3-hydroxybutane nitrile of formula (Ilia):
Figure imgf000018_0003
(Ilia).
PCT/KR2010/006346 2009-10-01 2010-09-16 Method for preparing intermediate of sitagliptin using chiral oxirane WO2011040717A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090093894A KR101253106B1 (en) 2009-10-01 2009-10-01 Method for preparing intermediate of sitagliptin using chiral oxirane
KR10-2009-0093894 2009-10-01

Publications (2)

Publication Number Publication Date
WO2011040717A2 true WO2011040717A2 (en) 2011-04-07
WO2011040717A3 WO2011040717A3 (en) 2011-10-13

Family

ID=43826758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/006346 WO2011040717A2 (en) 2009-10-01 2010-09-16 Method for preparing intermediate of sitagliptin using chiral oxirane

Country Status (4)

Country Link
KR (1) KR101253106B1 (en)
AR (1) AR079102A1 (en)
TW (1) TW201118101A (en)
WO (1) WO2011040717A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838511A (en) * 2011-06-24 2012-12-26 浙江海翔药业股份有限公司 Sitagliptin intermediates as well as preparation method and application of intermediate
CN113979853A (en) * 2021-11-24 2022-01-28 上海科利生物医药有限公司 Preparation method of (S) -3-hydroxy-4- (2,4, 5-trifluorophenyl) butyric acid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2108767A2 (en) * 1970-10-02 1972-05-26 Synthelabo 2-carbamyloxy-3-phenylbutyronitriles - with hypnotic activity
WO2004087650A2 (en) * 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
WO2009045507A2 (en) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Processes for preparing an intermediate of sitagliptin via enzymatic reduction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090192326A1 (en) 2007-11-13 2009-07-30 Nurit Perlman Preparation of sitagliptin intermediate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2108767A2 (en) * 1970-10-02 1972-05-26 Synthelabo 2-carbamyloxy-3-phenylbutyronitriles - with hypnotic activity
WO2004087650A2 (en) * 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
WO2009045507A2 (en) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Processes for preparing an intermediate of sitagliptin via enzymatic reduction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOHN W. KRAMER ET AL.: 'Fluorinated beta-lactones and poly(beta-hydroxyalkanoate)s : synthesis via epoxide carbonylation and ring-opening polymerization' TETR AHEDRON. vol. 64, 2008, pages 6973 - 6978 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838511A (en) * 2011-06-24 2012-12-26 浙江海翔药业股份有限公司 Sitagliptin intermediates as well as preparation method and application of intermediate
CN113979853A (en) * 2021-11-24 2022-01-28 上海科利生物医药有限公司 Preparation method of (S) -3-hydroxy-4- (2,4, 5-trifluorophenyl) butyric acid

Also Published As

Publication number Publication date
KR20110036308A (en) 2011-04-07
TW201118101A (en) 2011-06-01
WO2011040717A3 (en) 2011-10-13
KR101253106B1 (en) 2013-04-10
AR079102A1 (en) 2011-12-28

Similar Documents

Publication Publication Date Title
US8624026B2 (en) Method of preparing sitagliptin and intermediates used therein
CN86105558A (en) The preparation method of new (4-replaces-piperazinyl) pyridazine class
JP2010500343A (en) Chemical production of aromatic cyclopropane esters and amides
CN102702067B (en) Novel intermediate for synthesizing silodosin as well as preparation method and purpose of novel intermediate
CN104805142B (en) A kind of application of alcohol dehydrogenase in asymmetric reduction reaction
CN1035823A (en) 1, the 4-Disubstituted-piperidnyl compounds
JP6857219B2 (en) Method for preparing pyrimidinyl cyclopentane compound
JP2005247828A (en) Method for producing optically active serine derivative
WO2011040717A2 (en) Method for preparing intermediate of sitagliptin using chiral oxirane
CN103922971A (en) Improved Method For Preparing Intermediate Of Dipeptidyl Peptidase-iv Inhibitor
KR20110011606A (en) Process for the preparation of donepezil hydrochloride
CN87104641A (en) 4-(aromatic acylamino) piperidines butyramide derivative
CN108314688A (en) A kind of synthetic method of sitagliptin
JP2003277380A (en) Optically active 3-quinuclidinol
CN110003218B (en) Preparation method of Allagliptin intermediate
CN113264839B (en) Method for preparing levo-terbutaline by using chiral prosthetic group
JP2019513805A (en) Process for producing D-4,4&#39;-biphenylalanine alkyl ester or L-4,4&#39;-biphenylalanine alkyl ester from DL-4,4&#39;-biphenylalanine alkyl ester
JP2004155770A (en) Method for producing optically active amino alcohol
JP2008169204A (en) Method for preparing (1r, 2r)-2-amino-1-cyclopentanol
JPS63503384A (en) Effective stereoconservative synthesis of 1-substituted (S)- and (R)-2-aminomethylpyrrolidines and their intermediates
JP2003137835A (en) Method for producing (r)-3-hydroxy-3-(2-phenyl)hexanoic acid
JP4314602B2 (en) Process for producing optically active 3-hydroxypyrrolidine derivative
TWI294414B (en) Amino alcohol derivatives as amadorase inhibitors
JP2003342259A (en) Method for producing optically active cis-piperidine derivative
JP2005306804A (en) Method for producing optically active 3-quinuclidinol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10820790

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10820790

Country of ref document: EP

Kind code of ref document: A2